Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

MAO-inhibitors in Parkinson's Disease.

Riederer P, Laux G.

Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31.

2.

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

Guay DR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. Review.

PMID:
17296539
3.
4.

Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.

Finberg JP, Gross A, Bar-Am O, Friedman R, Loboda Y, Youdim MB.

Br J Pharmacol. 2006 Nov;149(6):647-56. Epub 2006 Oct 3.

5.

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Fernandez HH, Chen JJ.

Clin Neuropharmacol. 2007 May-Jun;30(3):150-68. Review.

PMID:
17545750
6.

Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.

Lecht S, Haroutiunian S, Hoffman A, Lazarovici P.

Ther Clin Risk Manag. 2007 Jun;3(3):467-74.

7.

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

Fernandez HH, Chen JJ.

Pharmacotherapy. 2007 Dec;27(12 Pt 2):174S-185S. Review.

PMID:
18041937
8.

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

Chen JJ, Ly AV.

Am J Health Syst Pharm. 2006 May 15;63(10):915-28. Review.

PMID:
16675649
9.
10.

Rasagiline in treatment of Parkinson's disease.

Nayak L, Henchcliffe C.

Neuropsychiatr Dis Treat. 2008 Feb;4(1):23-32.

11.

Clinical applications of MAO-inhibitors.

Riederer P, Lachenmayer L, Laux G.

Curr Med Chem. 2004 Aug;11(15):2033-43. Review.

PMID:
15279566
12.

Selegiline and rasagiline: twins or distant cousins?

Knudsen Gerber DS.

Consult Pharm. 2011 Jan;26(1):48-51. doi: 10.4140/TCP.n.2011.48. Review. Erratum in: Consult Pharm. 2012 Feb;27(2):70.

PMID:
21224199
14.
15.

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Schapira AH.

CNS Drugs. 2011 Dec 1;25(12):1061-71. doi: 10.2165/11596310-000000000-00000. Review.

PMID:
22133327
16.

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.

Finberg JP.

Rambam Maimonides Med J. 2010 Jul 2;1(1):e0003. doi: 10.5041/RMMJ.10003. Print 2010 Jul.

18.

The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.

Sieradzan K, Channon S, Ramponi C, Stern GM, Lees AJ, Youdim MB.

J Clin Psychopharmacol. 1995 Aug;15(4 Suppl 2):51S-59S.

PMID:
7593732
19.

The current status of monoamine oxidase and its inhibitors.

Jarrott B, Vajda FJ.

Med J Aust. 1987 Jun 15;146(12):634-8. Review.

PMID:
3114597
20.

The role of rasagiline in the treatment of Parkinson's disease.

Leegwater-Kim J, Bortan E.

Clin Interv Aging. 2010 May 25;5:149-56. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk